1-hexadecyl-2-acetyl-glycero-3-phosphocholine has been researched along with Auricular Fibrillation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, YD; Guo, YT; Liu, HB; Tao, T; Wang, H; Wang, HJ; Wang, YT; Zhao, XN | 1 |
| Argenziano, M; Besana, A; Comas, GM; Danilo, P; Feinmark, SJ; Harleton, E; Robinson, RB; Rosen, MR; Rosen, TS | 1 |
| Ansley, DM; English, JC; Godin, DV; Kim, CW; Lee, JU; Loucks, EB; Qayumi, AK | 1 |
3 other study(ies) available for 1-hexadecyl-2-acetyl-glycero-3-phosphocholine and Auricular Fibrillation
| Article | Year |
|---|---|
Prognostic factors of clinical endpoints in elderly patients with atrial fibrillation during a 2-year follow-up in China: An observational cohort study.
Topics: Age Factors; Aged; Aged, 80 and over; Atrial Fibrillation; Body Mass Index; C-Reactive Protein; Case-Control Studies; China; Digoxin; Female; Fibrinolytic Agents; Follow-Up Studies; Hemorrhage; Humans; Male; Platelet Activating Factor; Prognosis; Proportional Hazards Models; Prospective Studies; Thromboembolism | 2017 |
Ability to induce atrial fibrillation in the peri-operative period is associated with phosphorylation-dependent inhibition of TWIK protein-related acid-sensitive potassium channel 1 (TASK-1).
Topics: Animals; Atrial Fibrillation; CHO Cells; Cricetinae; Cricetulus; Dogs; Electrophysiology; Humans; Inflammation; Male; Muscle Cells; Nerve Tissue Proteins; Perioperative Period; Peroxidase; Phosphorylation; Platelet Activating Factor; Potassium Channels, Tandem Pore Domain; Protein Kinase C; Threonine | 2013 |
The role of platelet-activating factor in regional myocardial ischemia-reperfusion injury.
Topics: Animals; Arrhythmias, Cardiac; Atrial Fibrillation; Blood Pressure; Cardiac Output; Cardiac Volume; Disease Models, Animal; Female; Heart Arrest; Hemodynamics; Isoquinolines; Myocardial Contraction; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Neutrophils; Platelet Activating Factor; Platelet Aggregation Inhibitors; Pyridinium Compounds; Random Allocation; Stroke Volume; Swine; Tetrahydroisoquinolines; Ventricular Fibrillation; Ventricular Function | 1998 |